Pancreatic Cancer Breakthrough: Targeting Clotting Proteins for Improved Outcomes
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered a promising new avenue for treating pancreatic cancer: reducing levels of fibrinogen, a clotting protein produced by the liver. This discovery, published in Gastroenterology, suggests that targeting the blood clotting system, rather than simply viewing it as a byproduct of the disease, could significantly slow cancer progression.
The Link Between Blood Clots and Pancreatic Cancer
Pancreatic cancer patients are known to have unusually high rates of blood clots. Melissa L. Fishel, PhD, associate professor of pediatrics at the IU School of Medicine, and her team investigated whether these clots actively contribute to the disease. Their research indicates that fibrinogen, when deposited on pancreatic tumors, fosters an environment conducive to tumor growth.
“It’s well known that pancreatic cancer patients have some of the highest rates of blood clots,” said Fishel. “We wanted to understand whether the proteins involved in blood coagulation and clotting are driving the disease or are a byproduct of the disease.”
How Reducing Fibrinogen Impacts Tumor Growth
In mouse models, depleting fibrinogen led to a dramatic reduction in both primary tumor size and the spread of cancer to the liver. Researchers used two different methods to achieve this depletion, consistently observing positive results. Importantly, the study found that the impact of fibrinogen was most significant at the primary tumor site, altering the behavior of cancer cells before they could metastasize.
“When fibrin was not there, we saw a dramatic reduction in primary tumor size as well as liver lesions,” Fishel explained. “When pancreatic cancer spreads to the liver the patient prognosis is grim, so we were very excited by the possibility of reducing that tumor burden, and metastasis.”
The Importance of the Tumor Microenvironment
Pancreatic cancer is characterized by a dense, fibrotic microenvironment. Researchers discovered very little fibrin deposition in healthy pancreatic tissue, but abundant fibrin was present in tumor samples. This suggests that fibrin plays a key role in creating a supportive matrix for tumor cells, recruiting cancer-associated fibroblasts that further promote growth.
Future Directions: Combining Therapies and Targeted Approaches
While reducing fibrinogen slowed disease progression in mouse models, it didn’t eliminate the cancer entirely. The next step is to explore combining fibrinogen-targeted approaches with existing treatments like chemotherapy or emerging pancreatic cancer therapies. The goal is to understand precisely how fibrin influences tumor behavior and leverage this knowledge to enhance treatment effectiveness.
“Now we want to understand what fibrin is turning on or off in the tumor so we can combine treatments to craft them more effective,” Fishel said.
Researchers utilized tumor cell models, including those derived from IU patient samples, developed by the cancer center’s Pancreatic Cancer Working Group.
The Indiana University Simon Comprehensive Cancer Center: A Leader in Research
The Indiana University Melvin and Bren Simon Comprehensive Cancer Center is Indiana’s only National Cancer Institute-designated comprehensive cancer center. It’s one of only 57 in the nation and a member of the National Comprehensive Cancer Network, influencing the standard of care for cancer patients. The center conducts all phases of cancer research, from laboratory studies to clinical trials, with nearly 250 researchers involved.
Did you know?
The cure for testicular cancer was originally discovered at Indiana University, marking a 50th anniversary in 2024.
Frequently Asked Questions
Q: Will eliminating fibrinogen completely cure pancreatic cancer?
A: No, studies have shown that reducing fibrinogen slows disease progression, but a cure requires further research and combination therapies.
Q: Is it safe to lower fibrinogen levels in patients?
A: The goal is not to eliminate fibrinogen entirely, as it’s essential for preventing excessive bleeding. Researchers aim to return levels to a normal baseline.
Q: What is the Pancreatic Cancer Stromal Reprogramming Consortium?
A: It’s a national collaboration focused on accelerating discoveries in pancreatic cancer research.
Q: Where can I find more information about the IU School of Medicine?
A: You can visit their website at medicine.iu.edu.
Pro Tip: Early detection is crucial for pancreatic cancer. Discuss your risk factors with your doctor and be aware of potential symptoms.
Stay informed about the latest advancements in cancer research. Explore more articles on our website and subscribe to our newsletter for updates.
